Compare TSHA & SAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSHA | SAM |
|---|---|---|
| Founded | 2019 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2020 | 1996 |
| Metric | TSHA | SAM |
|---|---|---|
| Price | $5.66 | $170.75 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 11 |
| Target Price | $11.63 | ★ $233.70 |
| AVG Volume (30 Days) | ★ 4.1M | 284.3K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.56 | ★ 95.45 |
| EPS | ★ N/A | N/A |
| Revenue | $9,773,000.00 | ★ $1,964,994,000.00 |
| Revenue This Year | N/A | $1.02 |
| Revenue Next Year | $1,152.42 | $1.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.28 | N/A |
| 52 Week Low | $2.53 | $158.68 |
| 52 Week High | $7.30 | $264.46 |
| Indicator | TSHA | SAM |
|---|---|---|
| Relative Strength Index (RSI) | 43.52 | 43.68 |
| Support Level | $5.28 | $166.36 |
| Resistance Level | $6.01 | $188.80 |
| Average True Range (ATR) | 0.45 | 7.32 |
| MACD | -0.10 | 0.10 |
| Stochastic Oscillator | 24.09 | 18.51 |
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.